1 / 59

Advanced NSCLC: Treatment algorithms 2014

Advanced NSCLC: Treatment algorithms 2014. Prof. Christian Manegold Medical Faculty Mannheim University of Heidelberg. NSCLC: Incidence of single driver mutations. Mutation found in 54% (280/516) of tumours completely tested (CI 50-59%).

dwight
Download Presentation

Advanced NSCLC: Treatment algorithms 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advanced NSCLC: Treatment algorithms 2014 Prof. Christian Manegold Medical Faculty Mannheim University of Heidelberg

  2. NSCLC: Incidence of single driver mutations Mutation found in 54% (280/516) oftumours completely tested (CI 50-59%) Kris et al. J Clin Oncol 29 (suppl 15) 477 (abstr 7506); 2011

  3. Advanced NSCLC: Current Treatment algorithm Wild type tumors Mutant tumors Non-Squamous Squamous Platinum-Doublets (Pem!) plus Bev Platinum-Doublets (No Pem, no Bev) EGFR-TKI 1st-line Switch: Pemetrexed Erlotinib Continuous: Pemetrexed Switch: Erlotinib Treatment until progression Maintenance Oligo progression: Cont. TKI + Local therapy Diffuse progression Cont. TKI + Chemo Chemo  TKI re-expo 2nd generation TKI Single agent Non-cross resistant 2nd-line Single agent Non-cross resistant ALK-Inhibitor

  4. Advanced NSCLC: Treatment for non-mutant tumors • First-line – (induction) – therapy • Selection by histo-type • Maintenance therapy • Switch / continuation • Second-line / subsequent-line therapy

  5. NSCLC: International treatment recommendations for advanced disease • Chemotherapy prolongs survival and is most appropriate for individuals with good performance status (PS 0 or 1, and possibly 2). • Chemotherapy should be a platinum-based two-drug combination regimen. • Non-platinum containing regimens may be used as alternatives to platinum-based regimens. For elderly patients, or patients with PS 2, available data support the use of single-agent chemotherapy. • Chemotherapy should be stopped at 4 cycles in patients who are not responding to treatment, and should be administered for no more than six cycles. • If chemotherapy is to be given it should be initiated while the patient still has good PS. Azzoli et al. J Clin Oncol 29, 3825-3831, 2011 Peters et al. Ann Oncol 23 (Suppl 7), 56-64, 2012

  6. Advanced NSCLC: Medical management – practical aspects • Feasibility / tolerability: Cis-platin vs carbo-platin • Hotta et al. J Clin Oncol 22, 3852-3859, 2004, Rudd et al. J Clin Oncol 23, 142-153, 2005 • Artizoni et al. J Natl Cancer Inst 99, 847-857, 2007 • Co-morbidity / regimen: Platin based / free • D‘Addario et al. J Clin Oncol 23, 2926-2936, 2005 • Laack et al. J Clin Oncol 22, 2348-2356, 2004, • Age ≥ 70 years: Single agent / combination • Gridelli et al. J Clin Oncol 23, 3125-3137, 2005; Gridelli et al. J Natl Cancer Inst 95, 362-372, 2003 • Gridelli et al. J Natl Cancer Inst 91, 66-72, 1999; Sederholm et al. J Clin Oncol 23, 8380-8388, 2005 • Performance status ≥ 2: Single agent / combination • Gridelli et al. Ann Oncol 15, 419-426, 2004, • Patient’s expectations: Active therapy / BSC • Gridelli et al. J Clin Oncol 23, 3125-3137, 2005

  7. Selection by histo-type according to efficacy (non-squamous vs squamous)

  8. Advanced NSCLC: Treatment by histologyCisplatin plus Pemetrexed or Gemcitabine Squamous (n=473) Nonsquamous* (n=1252) HR=1.229 (95% CI: 1.00–1.51) p=0.051 HR=0.844 (95% CI: 0.74–0.96) p=0.011 Gemcitabine+Cisplatin Median OS: 10.8 mos Pemetrexed+Cisplatin Median OS: 11.0 mos Survival Probability Survival Probability Gemcitabine+Cisplatin Median OS: 10.1 mos Pemetrexed+Cisplatin Median OS: 9.4 mos Survival Time (months) Survival Time (months) Scagliotti et al J Clin Oncol, 26, 3543-3551, 2008

  9. Efficacy by Histology in Pemetrexed Studies Non-squamous = adenocarcinoma, large cell carcinoma, and other/indeterminate NSCLC histology Scagliotti et al. J ThoracOncol 6, 64-70, 2011

  10. Ifosfamide in NSCLC: MIC Regimen Mitomycin C 6 mg/m² i.v. Bolus day 1 Ifosfamide 3.000 mg/m² i.v./3 h day 1 Cisplatin 50 mg/m² i.v./1 h day 1 Cycle repeated q3w MESNA-Uroprotection 20 % (IFO) i.v. fractionated (0 hours) 4 h + 8 h 100 % (IFO) i.v. continuous (0 hours) during IFO + for additional 12 q 24 h Cullen et al, Br J Cancer 58, 359-361, 1988

  11. MIC `s Efficacy is not inferior to other Platinum Doublets n RR TTP MST 1-y-s Ref. NVB / CIS 206 30 % n.r. 9.5 mo* 37 % Le Chevalier VDS / CIS 200 19 % n.r. 7.6 mo 28 % (1994) PAC 135 / CIS Total 27 %* 4.5 mo* 9.6 mo* 37 % Bonomi PAC 250 / CIS 560 32 %* 5.3 mo* 10 mo* 39 % (1996) ETO / CIS 12 % 3.0 mo 7.7 mo 32 % GEM / CIS 154 40 % 4.8 mo 8.6 mo 33 % Crino MIC 152 28 % 5.0 mo 9.5 mo 34 % (1998) GEM / CIS 69 41 %* 6.9 mo* 8,7 mo 32 % Cardenal ETO / CIS 66 22 % 4.3 mo 7.2 mo 26 % (1999) PAC / CARBO 190 23 %* 4.0 mo 7.7 mo 32 % Belani ETO / CIS 179 14 % 3.3 mo 8.2 mo 37 % (1998) *p<.05

  12. Platinum-free, Ifosfamide based doublets have been developed PAC 250 mg/m² (3h), d 1 IFO 1600 mg/m² , d 1-3 q3w x 6 Arm A n=48 Arm B n=45 Phase II Stage IIIb/IV NAV 30 mg/m², d 1-3 IFO 1600 mg/m², d 1-3 q3w x 6 RR MS 1yS A: 38% 9mo 35% B: 31% 8mo 38% Perry et al, Lung Cancer 48,63-68, 2000

  13. Platinum-free, Ifosfamide based doublets have been developed Cis 100 mg/m², d 1 x 6 (n=166) Gem 1250 mg/m² , d 1, 8 Phase III Stage IIIb/IV PS 0-2 Cis 100 mg/m², d 1 x 6 (n=176) Gem 1000 mg/m², d 1, 8 Vin 25 mg/m², d 1, 8 Gem 1000 mg/m², d 1, 8 x 3 (n=175) Vin 30 mg/m², d 1, 8 Ifo 3000 mg/m², d 1 x 3 Vin 30 mg/m², d 1, 8 RR: 41% 40% 24% MS: 10m 8m 11m Ntp3/4: 26% 30% 18% Tbp3/4: 18% 23% 7%0 Alberola et al, J Clin Oncol, 21:3207-3213, 2003

  14. Selection by toxicity profile (non-squamous vs squamous)

  15. Advanced NSCLC: Bevacizumab plus Standard CT Results by primary endpoints ECOG 4599: Carbo/Taxol AVAiL: Cis/Gem 6.7 m 6.1 m 12.3 m 10.3 m 6.5 m 6.1 m Time Months Sandler et al N Engl J Med 355, 2542-2550, 2006 Reck et al, Ann Oncol 21, 1804-1809, 2010 Reck et al, J Clin Oncol 27, 1227-1235, 2009

  16. NSCLC: Bevacizumab - Eligibility Sandler et al N Engl J Med 355, 2542-2550, 2006 Crino et al, LancetOncol 11, 733-740, 2010 Reck et al, J ClinOncol 27, 1227-1235, 2009 Reck et al, Ann Oncol 21, 1227-1234,2010 Sandler et al J Thorac Oncol 5,1416-1423,2010 Soria et al Ann Oncol 24,20-30,2013

  17. Advanced NSCLC: Basics of medical management • First-line – (induction) – therapy • Selection by histo-type • Maintenance therapy • Switch / continuation • Second-line / subsequent-line therapy

  18. Advanced NSCLC:Medical Treatment in wild type tumors Traditional (standard) approach 1st-line 2nd-/subsequent line Combination orsingleagent CT definednumber of cycles (4-6) single agent , Non-cross-resistant until progression Tumor progression New (maintenance) approach 1st-line Maintenance Combination orsingleagent CT definednumber of cycles (4-6) • oneofthefirstlineagentsuntilprogression (continuation) • „new“ non-cross-resistantagentuntilprogression (switch) Non- progression 2nd-/subsequent line

  19. Advanced NSCLC: Switch/continuation maintenance Cappuzzo et al. Lancet Oncol 11, 521-529; 2010 Ciuleanu T. et al. Lancet 374, 1432-1440; 2009 Paz-Ares Lancet Oncol 13, 247-255, 2012 Zhang et al. Lancet Oncol 13, 466-475,2012 Fidias et al J ClinOncol 27, 591-598, 2008 Perol et al J ClinOncol 30, 3516-3524, 2012 Paz-Ares et al J ClinOncol 31, 2895-2902, 2013

  20. Advanced NSCLC: Maintenance Switch type („early second line“) • Docetaxel Fidias et al J Clin Oncol 27, 591-598, 2009

  21. Advanced NSCLC - Maintenance: Docetaxel following Standard Doublet Chemotherapy Immediate vs delayed (2nd-line) Docetaxel CR, PR SD n=142/153 n=552 Immediate Docetaxel75 mg/m2 d1, q3w x 6 R A N D O MI Z E • Stage IIIb/IV • ECOG PS = 0–2 • CNS Mets allowed Gem, 1000 mg/m2, d1, 8 Carbo AUC 5, d1, q3w x 4 Delayed Docetaxel75 mg/m2 d1, q3w x 6 Off study: n=245 n=91/154 n=307 Primary endpoint: overall survival Fidias et al., J Clin Oncol 27, 591-598, 2009

  22. Advanced NSCLC - Maintenance: Extension by Docetaxel following Standard Doublet Chemotherapy Immediate vs delayed (2nd-line) Docetaxel Overall survival time (months) Fidias et al., J Clin Oncol 27, 591-598, 2009

  23. Advanced NSCLC: Maintenance Switch type („early second line“) • Erlotinib Cappuzzo et al, Lancet Oncol 11, 521-529, 2010

  24. Advanced NSCLC: Erlotinib switch maintenance (Saturn) Erlotinib 150mg/day PD Chemonaïve advanced NSCLC n=1,949 4 cycles of first-line platinum doublet chemotherapy* Non-PD n=889 1:1 Stratification factors: • EGFR IHC (positive vs negative vs indeterminate) • Stage (IIIB vs IV) • ECOG PS (0 vs 1) • CT regimen (cis/gem vs carbo/doc vs others) • Smoking history (current vs former vs never) • Region Placebo PD Mandatory tumour sampling Co-primary endpoints: • PFS in all patients • PFS in patients with EGFR IHC+ tumours • Secondary endpoints: • OS in all patients and those with EGFR IHC+ tumours, OS and PFS in EGFR IHC– tumours; biomarker analyses; safety; time to symptom progression; QoL *Cisplatin/paclitaxel; cisplatin/gemcitabine; cisplatin/docetaxel cisplatin/vinorelbine; carboplatin/gemcitabine; carboplatin/docetaxel carboplatin/paclitaxel

  25. Advanced NSCLC: Erlotinib switch maintenanceProgression free survival Progression free Survival Cappuzzo et al. Lancet Oncol 11, 521-529; 2010

  26. Advanced NSCLC: Erlotinib switch maintenanceOverall survival Overall Survival Cappuzzo et al. Lancet Oncol 11, 521-529; 2010

  27. Advanced NSCLC: Erlotinib switch-maintenance Overall survival by response Stable disease CR/PR 1.0 0.8 0.6 0.4 0.2 0 1.0 0.8 0.6 0.4 0.2 0 HR=0.72 (0.59–0.89) HR=0.94 (0.74–1.20) Log-rank p=0.0019 Log-rank p=0.6181 Overall Survival 9.6 11.9 12.0 12.5 0 3 6 9 12 15 18 21 24 27 30 33 36 0 3 6 9 12 15 18 21 24 27 30 33 36 Time (months) Time (months) Coudert et al. Ann Oncol 23, 388-394, 2012 Cappuzzo et al. Lancet Oncol 11, 521-529; 2010 Measured from time of randomisation into the maintenance phase

  28. Advanced NSCLC: Maintenance Switch type („early second line“) • Pemetrexed Ciuleanu et al Lancet 374, 1432-1440, 2009

  29. AdvancedNSCLC: Pemetrexedswitchmaintenance • Stage IIIB/IV NSCLC • PS 0-1 • 4 prior cycles of gem, doc, or tax + cis or carb, with CR, PR, or SD • Randomization factors: • gender • PS • stage • best tumor response to induction • non-platinum induction drug • brain mets Pemetrexed 500 mg/m2 (d1,q21d) + BSC (N=441)* 2:1 Randomization Primary Endpoint = PFS Placebo (d1, q21d) + BSC (N=222)* *B12, FOLATE, AND DEXAMETHASONE GIVEN IN BOTH ARMS Ciuleanu T. et al. Lancet 374, 1432-1440; 2009

  30. Advanced NSCLC: Pemetrexed switch maintenanceProgression free survival by histology Squamous Non-squamous HR=1.03 (95% CI: 0.77-1.5) p=0.896 HR=0.47 (95% CI: 0.37-0.6) p <0.00001 Pemetrexed: 4.4 mos Placebo: 2.5 mos Progression-free Probability Placebo: 1.8 mos Pemetrexed: 2.4 mos Time (months) Time (months) Ciuleanu T. et al. Lancet 374, 1432-1440; 2009

  31. Advanced NSCLC: Pemetrexed switch maintenance Overall survival by histology Non-squamous Squamous HR=0.70 (95% CI: 0.56-0.88) p=0.002 HR=1.07 (95% CI: 0.49-0.73) p=0.678 Overall Survival Pemetrexed: 15.5 mos Placebo: 10.8 mos Pemetrexed: 9.9 mos Placebo: 10.3 mos Time (months) Time (months) Ciuleanu T. et al. Lancet 374, 1432-1440; 2009

  32. Advanced NSCLC: switch maintenance ASCO recommendations 2011 For patients with SD or response after 4 cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with non-squamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered (alternative to second-line therapy!) Azzoli et al. J Clin Oncol 29, 3825-3831, 2011 Fidias et al. J Clin Oncol 27, 591-598, 2009 Coudert et al. Ann Oncol 23, 388-394, 2012 Cappuzzo et al. Lancet Oncol 11, 521-529; 2010 Paz-Ares Lancet Oncol 13, 247-255, 2012

  33. Advanced NSCLC: Maintenance Continuation type („true maintenance“) • Pemetrexed

  34. Advanced NSCLC: Pemetrexed continuation maintenance (PARAMOUNT) Non PD Pemetrexed 3qw bis PD Stadium IV Non-squamous SD nach 4-6x Induktions-CT Cisplatin/Pemetrexed Randomisation 2:1 Placebo 3qw bis PD Paz-Ares et al Lancet Oncol 13, 247-255, 2012 Paz-Ares et al J Clin Oncol 31, 2895-2902, 2013

  35. Advanced NSCLC: Pemetrexed continuation maintenance (PARAMOUNT) – Overall survival by response Paz-Ares et al. J ClinOncol31, 2895-2902, 2013

  36. Advanced NSCLC: Pemetrexed registration Continuation maintenance therapy ......as single agent following platinum based therapy - predominantly other than squamous cell histology; non-progression after four cycles of chemotherapy…… EMA: 2011

  37. Advanced NSCLC - Maintenance Comparison switch vs continuation • Erlotinib (switch) • Gemcitabine (continuation) Perol et al J Clin Oncol 30, 3516-3524, 2012

  38. Advanced NSCLC: Erlotinib (switch) vs Gemcitabine (continuation) maintenance (IFCT-GFPC 0502) • Patients stratified by sex, histology, smoking status, treatment center, and response/stabilization following first-line therapy • Primary endpoint: PFS • Other endpoints: OS, safety, symptom control, effect of EGFR status Patients without disease progression randomized 1:1:1 Gemcitabine (n = 154) Pem 74 % Chemotherapy-naive patients with stage IIIB/IV NSCLC (N = 834) Cisplatin/Gemcitabine for 4 cycles Erlotinib (n = 155) Pem 75% Observation (n = 155) Pem 84% PerolM et al, J Clin Oncol 30, 3516-3524, 2012

  39. Advanced NSCLC: Erlotinib (switch) vs Gemcitabine (continuation) maintenance (IFCT-GFPC 0502) PerolM et al, J Clin Oncol 30, 3516-3524, 2012

  40. Advanced NSCLC: Basics of medical management • First-line – (induction) – therapy • Selection by histo-type • Maintenance therapy • Switch / continuation • Second-line / subsequent-line therapy

  41. Current ASCO Guidelines for NSCLC Docetaxel, EGFR-TKI’s, and Pemetrexed are acceptable as second-line therapy for patients with advanced NSCLC with adequate performance status when the disease has progressed during or after first-line platinum-based therapy Azzoli et al. J Clin Oncol 29, 3825-3831, 2011 Shepherd et al. N Engl J Med 353, 123-132, 2005 Thatcher et al. Lancet 366, 1527-1537, 2005 Hanna et al. J Clin Oncol 22, 1589-1597, 2004

  42. Advanced NSCLC: EGFR-TKIs as second-line therapy Kim et al. Cancer 116, 3025-3033, 2010 Karampazis et al. Cancer 119, 2754-2764, 2013 Garassino et al. Lancet Oncol 14, 981-988, 2013 Ciuleanu et al. Lancet Oncol 13, 300-308, 2012 Shepherd et al. N Engl J Med 353, 123-132, 2005 Kim et al. Lancet 372, 1809-1818, 2008 Thatcher et al. Lancet 366, 1527-1537, 2005

  43. Meta-analysis in wild-type NSCLC favors CT over EGFR-TKI therapy: First- / second-line Lee et al. JAMA 311,1430-1437, 2014

  44. Advanced NSCLC: Systemic therapy in the absence of driver mutations – Summary (1) • Chemotherapy remains standard for the majority of patients - (first-line; platinum doublets; 4 – 6 cycles) • The selection of the platinum-partner should depend on tumor histo-type - (non-squamous vs squamous; pemetrexed vs gemcitabine etc.) • Modification of the first-line standard is clinically advisable according to co-morbidity, performance status, and patient’s age - (single agent; platinum-free; BSC only) • Treatment until progression by the anti-angiogenicbevacizumab as recommended in selected patients - (eligibility criteria; group toxicity)

  45. Advanced NSCLC: Systemic therapy in the absence of driver mutations – Summary (2) • Prolongation of induction chemotherapy beyond 4 – 6 cycles for maintaining “response” until progression has been established as a new strategy - (switch/continuation maintenance) • Second/subsequent – line chemotherapy is recommended in patients with acceptable performance status - (single agent; docetaxel; pemetrexed) • EGFR-TKI’s have also been licensed for wild-type tumors - (maintenance; second/third-line therapy) • A tight cooperation between the pathologist and the clinician is critical - (histology – subtyping; molecular testing; result reporting)

  46. Advanced NSCLC: Current Treatment algorithm Wild type tumors Mutant tumors Non-Squamous Squamous Platinum-Doublets (Pem!) plus Bev Platinum-Doublets (No Pem, no Bev) EGFR-TKI 1st-line Switch: Pemetrexed Erlotinib Continuous: Pemetrexed Switch: Erlotinib Treatment until progression Maintenance Oligo progression: Cont. TKI + Local therapy Diffuse progression Cont. TKI + Chemo Chemo  TKI re-expo 2nd generation TKI Single agent Non-cross resistant 2nd-line Single agent Non-cross resistant ALK-Inhibitor

  47. Advanced NSCLC: EGFR-TKIs as first line therapy Mok et al. N Engl J Med, 361, 947-957, 2009 Rosell et al Lancet Oncol 13;239-246;2012 Lee et al Lancet Oncol 13, 1161-1170, 2012 Zhou et al. Lancet Oncol 12, 735-742, 2011 Mitsudomi et al Lancet Oncol 11, 121-128, 2010 Sequist et al. J ClinOncol 31, 3327-3334, 2013 Gridelli et al J ClinOncol 30, 3002-3011, 2012

  48. First-linetrials of EGFR tyrosinekinaseinhibitors vs. chemotherapy in pts with EGFR mutations 1. Mok T et al., N Engl J Med 2009;361:947–957; 2. Fukuoka M et al., J Clin Oncol 2011; 29:2866‒2874; 3. Han J-Y et al., J Clin Oncol 2012; 30:1122‒128; 4. Maemondo M et al., N Engl J Med 2010;362:2380–2388; 5. Mitsudomi T et al., Lancet Oncol 2010;:121–128; 6. Zhou C et al., Lancet Oncol2011;12:735‒742; 7. Rosell R et al., Lancet Oncol 2012;13:239–246; 8. Yang JC et al., J Clin Oncol2012;30 (Suppl. 16):LBA 7500, Wu Y et al., Lancet 2014; 15:213. NR = not reported

  49. Advanced NSCLC: First-line EGFR-TKI therapyASCO / ESMO-recommendation … EGFR-TKI therapy should be prescribed for patients with tumors bearing activated EGFR-mutations … … Patients with PS 3-4 may also be offered EGFR-TKI treatment … Azzoli et al. J Clin Oncol 29, 3825-3831, 2011 Peters et al. Ann Oncol 23 (Suppl 7), 56-64, 2012

  50. EGFR mutations: whom to test? (1) EGFR molecular testing should be used to select patients for EGFR-targeted TKI therapy, and patients with lung adenocarcinoma should not be excluded from testing on the basis of clinical characteristics Lindeman et al., J Thorac Oncol, 823-859, 2013

More Related